| Schedule of Reporting Segment |
| | | | | | | | | | | | | Three Months Ended
March 31, | | 2025 | | 2024 | | Revenue | $ | 7 | | | $ | 3 | | | Operating expenses: | | | | | Research and development | | | | | Technical operations | 21,833 | | | 17,271 | | Clinical development | 8,919 | | | 8,383 | | Non-clinical research | 5,146 | | | 10,528 | | | Facilities and technology | 7,549 | | | 6,992 | | | Total research and development expenses | 43,447 | | | 43,174 | | | General and administrative | | | | | Business support | 9,071 | | | 8,916 | | | Corporate expenses and outside services | 3,831 | | | 3,668 | | | Facilities and technology | 1,144 | | | 910 | | | Total general and administrative expenses | 14,046 | | | 13,494 | | | Other operating income, net | (119) | | | (1,090) | | | Total operating expenses | 57,374 | | | 55,578 | | | Loss from operations | (57,367) | | | (55,575) | | | Interest income, net | 3,862 | | | 6,819 | | | Other income, net | 1,310 | | | 1,090 | | | Impairment of other investments | — | | | (13,001) | | | Total other income, net | 5,172 | | | (5,092) | | | Net loss | $ | (52,195) | | | $ | (60,667) | |
|